Security
OPKO Health, Inc. Common Stock · OPK
OPKNASDAQCommon stockCurrentCIK 944809Updated Oct 16, 2026
Name history
EXEGENICS INC · through Jun 13, 2007eXegenics Inc · through Jun 13, 2007CYTOCLONAL PHARMACEUTICS INC /DE · through Jun 4, 2001
OPK price & chart
Loading TradingView…
NASDAQ:OPK on TradingView ↗About the company
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and novel and proprietary technologies. For more information, please visit www.opko.com.
In the news
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026 ↗
Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses News provided by Labcorp Holdings Inc Sep 15, 2025, 08:30 ET Share this article Share to X Share this article Share to X BURLINGTON, N.C. and MIAMI , Sept. 15, ↗
NextPlat Issues Interim CEO Update Shareholder Letter News provided by NextPlat Corp. Jun 30, 2025, 08:01 ET Share this article Share to X Share this article Share to X COCONUT GROVE, Fla. , June 30, 2025 /PRNewswire/ -- NextPlat Corp ( NASDAQ: NXPL , NXPLW ) ("NextPlat" or the "Company"), a global ↗
Recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Other Events
Items 8.01
10-Q/A filing
10-Q/A filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,995,508,000Source | 2,256,103,000Source | 1,829,453,000Source | 1,972,989,000Source | 1,979,871,000Source | 1,856,796,000Source | 2,128,327,000Source | 1,974,016,000Source | 1,931,944,000Source | 2,200,212,000Source | 2,011,698,000Source | 2,167,259,000Source |
| Property, Plant and Equipment, NetUSD | 74,994,000Source | — | 71,454,000Source | 74,937,000Source | 66,766,000Source | 72,585,000Source | 71,195,000Source | 64,165,000Source | 73,926,000Source | 70,134,000Source | 75,429,000Source | — |
| GoodwillUSD | 484,032,000Source | 535,868,000Source | 481,515,000Source | 484,185,000Source | 530,106,000Source | 482,268,000Source | 476,672,000Source | 530,615,000Source | 484,289,000Source | 529,252,000Source | 598,260,000Source | 595,851,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 535,378,000Source | 641,396,000Source | 477,566,000Source | 555,988,000Source | 659,111,000Source | 496,351,000Source | 568,518,000Source | 680,034,000Source | 516,276,000Source | 616,613,000Source | 740,283,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 411,972,000Source | 400,079,000Source | 300,761,000Source | 267,280,000Source | 40,576,000Source | 331,862,000Source | 428,831,000Source | 75,639,000Source | 364,409,000Source | 426,582,000Source | 95,881,000Source | 153,191,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 94,580,000Source | 106,579,000Source | 81,886,000Source | 99,376,000Source | 105,313,000Source | 79,636,000Source | 96,150,000Source | 111,367,000Source | 90,255,000Source | 118,017,000Source | 123,379,000Source | 127,312,000Source |
| Inventory, NetUSD | 64,954,000Source | 59,408,000Source | 61,851,000Source | 66,345,000Source | 60,153,000Source | 64,397,000Source | 64,001,000Source | 59,366,000Source | 65,823,000Source | 56,797,000Source | 65,697,000Source | 74,060,000Source |
| Assets, CurrentUSD | 627,130,000Source | 629,636,000Source | 500,236,000Source | 583,333,000Source | 357,981,000Source | 535,362,000Source | 737,604,000Source | 391,303,000Source | 581,881,000Source | 662,089,000Source | 309,476,000Source | 394,525,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 52,398,000Source | 57,249,000Source | 55,738,000Source | 58,883,000Source | 32,288,000Source | 49,448,000Source | 54,441,000Source | 24,652,000Source | 56,729,000Source | 55,339,000Source | 24,519,000Source | 39,962,000Source |
| Operating Lease, Right-of-Use AssetUSD | 45,681,000Source | 62,812,000Source | 43,971,000Source | 46,627,000Source | 61,622,000Source | 45,800,000Source | 47,819,000Source | 63,331,000Source | 46,930,000Source | 54,003,000Source | 68,088,000Source | 38,725,000Source |
| Other Assets, NoncurrentUSD | 19,926,000Source | 18,511,000Source | 19,494,000Source | 19,874,000Source | 7,796,000Source | 18,901,000Source | 18,769,000Source | 8,578,000Source | 19,474,000Source | 18,537,000Source | 9,080,000Source | 8,679,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 690,018,000Source | 852,686,000Source | 645,287,000Source | 676,085,000Source | 584,554,000Source | 652,186,000Source | 816,664,000Source | 721,208,000Source | 663,985,000Source | 834,764,000Source | 622,479,000Source | 605,611,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 7,990,000Source | 7,124,000Source | 7,762,000Source | 8,097,000Source | 7,273,000Source | 7,850,000Source | 7,015,000Source | 7,269,000Source | 7,900,000Source | 7,015,000Source | 7,820,000Source | 7,813,000Source |
| Additional Paid in CapitalUSD | 3,584,789,000Source | 3,516,735,000Source | 3,561,114,000Source | 3,596,392,000Source | 3,540,414,000Source | 3,571,575,000Source | 3,484,068,000Source | 3,386,147,000Source | 3,574,942,000Source | 3,481,364,000Source | 3,433,006,000Source | 3,421,872,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,259,433,000Source | -2,079,037,000Source | -2,353,954,000Source | -2,281,064,000Source | -2,103,927,000Source | -2,345,538,000Source | -2,132,623,000Source | -2,093,622,000Source | -2,290,690,000Source | -2,065,010,000Source | -2,011,786,000Source | -1,822,923,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -25,466,000Source | -39,614,000Source | -28,393,000Source | -24,730,000Source | -46,652,000Source | -27,486,000Source | -45,006,000Source | -45,195,000Source | -21,017,000Source | -56,130,000Source | -38,030,000Source | -43,323,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,305,490,000Source | 1,403,417,000Source | 1,184,166,000Source | 1,296,904,000Source | 1,395,317,000Source | 1,204,610,000Source | 1,311,663,000Source | 1,252,808,000Source | 1,267,959,000Source | 1,365,448,000Source | 1,389,219,000Source | — |
| Liabilities and EquityUSD | 1,995,508,000Source | 2,256,103,000Source | 1,829,453,000Source | 1,972,989,000Source | 1,979,871,000Source | 1,856,796,000Source | 2,128,327,000Source | 1,974,016,000Source | 1,931,944,000Source | 2,200,212,000Source | 2,011,698,000Source | 2,167,259,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 169,321,000Source | 211,660,000Source | 149,367,000Source | 171,181,000Source | 219,553,000Source | 148,383,000Source | 295,854,000Source | 204,338,000Source | 146,677,000Source | 193,096,000Source | 200,052,000Source | 213,480,000Source |
| Operating Lease, Liability, CurrentUSD | 10,106,000Source | 12,741,000Source | 11,009,000Source | 9,919,000Source | 11,624,000Source | 11,086,000Source | 9,888,000Source | 11,742,000Source | 10,917,000Source | 12,649,000Source | 12,996,000Source | 11,628,000Source |
| Accounts Payable, CurrentUSD | 50,827,000Source | 62,721,000Source | 50,043,000Source | 56,683,000Source | 82,242,000Source | 44,176,000Source | 59,370,000Source | 71,157,000Source | 41,103,000Source | 47,071,000Source | 69,677,000Source | 66,993,000Source |
| Operating Lease, Liability, NoncurrentUSD | 36,273,000Source | 52,057,000Source | 33,980,000Source | 37,291,000Source | 49,624,000Source | 35,636,000Source | 38,344,000Source | 50,931,000Source | 36,815,000Source | 48,849,000Source | 54,140,000Source | 27,963,000Source |
| Deferred Income Tax Liabilities, NetUSD | 130,341,000Source | 128,412,000Source | 108,230,000Source | 113,328,000Source | 119,120,000Source | 114,562,000Source | 129,435,000Source | 121,635,000Source | 126,241,000Source | 140,799,000Source | 126,773,000Source | 126,426,000Source |
| Other Liabilities, NoncurrentUSD | 25,160,000Source | 36,504,000Source | 16,999,000Source | 27,807,000Source | 20,315,000Source | 19,582,000Source | 30,011,000Source | 21,196,000Source | 22,799,000Source | 32,838,000Source | 27,189,000Source | 27,371,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 95,603,000Source | 122,806,000Source | 77,757,000Source | 90,555,000Source | 94,516,000Source | 83,476,000Source | 113,209,000Source | 88,772,000Source | 84,406,000Source | 118,357,000Source | 90,086,000Source | 98,269,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 123,414,000Source | 138,448,000Source | 123,291,000Source | 123,263,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 2,509,000Source | 3,529,000Source | 1,781,000Source | 2,773,000Source | 3,676,000Source | 2,007,000Source | 2,833,000Source | 4,036,000Source | 2,262,000Source | 3,002,000Source | 7,727,000Source | 256,251,000Source |
| Long-term Debt, Current MaturitiesUSD | 1,463,000Source | 1,509,000Source | 912,000Source | 1,519,000Source | 1,597,000Source | 1,528,000Source | 1,425,000Source | 1,822,000Source | 343,966,000Source | 1,384,000Source | 1,993,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 2,509,000Source | 3,529,000Source | 1,781,000Source | 2,773,000Source | 3,676,000Source | 2,007,000Source | 2,833,000Source | 4,036,000Source | 2,262,000Source | 3,002,000Source | 7,727,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 22,739,000Source | 24,163,000Source | 22,409,000Source | 23,027,000Source | 22,201,000Source | 23,487,000Source | 91,627,000Source | 98,176,000Source | 105,297,000Source | 108,655,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 3,000,000Source | 2,800,000Source | 2,200,000Source | 2,200,000Source | 2,735,000Source | 2,616,000Source | 10,714,000Source | 11,048,000Source | 11,413,000Source | 18,509,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -9,526,000Source | -22,930,000Source | -30,213,000Source | 220,000Source | -3,411,000Source | -128,602,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -191,000Source | 5,437,000Source | 4,118,000Source | -4,217,000Source | -15,197,000Source | -13,662,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 3,496,000Source | 11,475,000Source | -14,217,000Source | -20,662,000Source | 2,828,000Source | -9,388,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | -7,890,000Source | -7,424,000Source | -14,999,000Source | 14,744,000Source | 146,000Source | -74,405,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -19,310,000Source | -34,554,000Source | -178,542,000Source | -183,489,000Source | -28,197,000Source | -95,189,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 1,758,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -1,800,000Source | 40,528,000Source | 230,296,000Source | 352,214,000Source | -18,198,000Source | 91,038,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 4,767,000Source | 0Source | 47,040,000Source | 90,223,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -5,157,000Source | -4,022,000Source | -118,056,000Source | 184,166,000Source | -11,303,000Source | 22,971,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -27,175,000Source | 4,062,000Source | -62,873,000Source | 349,734,000Source | -57,310,000Source | 18,481,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 428,874,000Source | 420,065,000Source | 314,432,000Source | 285,395,000Source | 355,567,000Source | 449,677,000Source | 382,742,000Source | 445,615,000Source | 95,881,000Source | 153,191,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 9,603,000Source | 13,762,000Source | 37,936,000Source | 20,883,000Source | 8,135,000Source | 7,420,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | -2,573,000Source | 2,059,000Source | 24,463,000Source | 10,008,000Source | 3,712,000Source | 8,037,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | — | — | -339,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | 10,700,000Source | 11,000,000Source | 11,400,000Source | — |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 137,000Source | 430,000Source | 5,234,000Source | 1,974,000Source | 1,222,000Source | 1,161,000Source |
| Amortization of Intangible AssetsUSD | — | — | 19,531,000Source | 20,433,000Source | 18,969,000Source | 19,444,000Source | 18,966,000Source | 19,861,000Source | 77,890,000Source | 82,634,000Source | 86,032,000Source | 87,784,000Source |
| DepreciationUSD | — | — | 3,200,000Source | 3,700,000Source | 3,400,000Source | 3,600,000Source | 3,200,000Source | 3,600,000Source | 13,700,000Source | 15,600,000Source | 19,300,000Source | 20,900,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | 121,493,000Source | — | — | — | — | 101,576,000Source | 121,493,000Source | — | — |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | — | — | — | — | -3,646,000Source | 2,165,000Source | 4,084,000Source | 73,873,000Source | -532,000Source | -3,578,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | -3,938,000Source | -4,324,000Source | -54,026,000Source | 0Source | 0Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | — | — | — | — | -3,646,000Source | -1,773,000Source | -240,000Source | 19,847,000Source | -532,000Source | -3,578,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 1,100,000Source | 4,100,000Source | 100,000Source | 2,600,000Source | 1,500,000Source | 100,000Source | -2,000,000Source | -3,800,000Source | 1,200,000Source | -1,800,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | -38,000Source | -1,000Source | -65,000Source | 16,000Source | -298,000Source | -273,000Source | -429,000Source | -26,161,000Source | -781,000Source | 649,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | 34,000Source | 3,786,000Source | 3,245,000Source | 63,397,000Source | -1,321,000Source | 455,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | -3,000Source | — | — | — | — | — | — | -107,000Source | -383,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 18,559,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | 101,576,000Source | 121,493,000Source | 18,070,000Source | 0Source | — | — | 101,576,000Source | 121,493,000Source | 0Source | 18,559,000Source |
| GoodwillUSD | — | — | 484,032,000Source | 535,868,000Source | 481,515,000Source | 484,185,000Source | 482,268,000Source | 476,672,000Source | 484,289,000Source | 529,252,000Source | 598,260,000Source | 595,851,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 1,007,000Source | 0Source | 0Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -3,000Source | -3,000Source | 0Source | 0Source | -2,000Source | -9,000Source | -29,000Source | -18,000Source | -107,000Source | -383,000Source |
| Income Tax Expense (Benefit)USD | — | — | 19,797,000Source | 23,527,000Source | -4,983,000Source | -14,079,000Source | -6,110,000Source | -5,770,000Source | -15,713,000Source | 42,844,000Source | 4,437,000Source | -63,499,000Source |
| Induced Conversion of Convertible Debt ExpenseUSD | — | — | — | — | — | — | — | — | 32,647,000Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 11,358,000Source | 17,359,000Source | 11,380,000Source | 70,327,000Source | 10,939,000Source | 15,466,000Source | 108,462,000Source | 47,465,000Source | — | — |
| Inventory Write-downUSD | — | — | 1,200,000Source | 600,000Source | 1,500,000Source | 2,300,000Source | 800,000Source | 800,000Source | 4,100,000Source | 2,100,000Source | 8,100,000Source | 4,100,000Source |
| Investment Income, InterestUSD | — | — | 3,023,000Source | 2,928,000Source | 3,221,000Source | 3,287,000Source | 3,007,000Source | 4,681,000Source | 14,811,000Source | 8,426,000Source | 3,983,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 21,631,000Source | 24,890,000Source | -8,416,000Source | -148,441,000Source | -54,848,000Source | -67,613,000Source | -225,680,000Source | -53,224,000Source | -188,863,000Source | -328,405,000Source |
| Nonoperating Income (Expense)USD | — | — | -6,625,000Source | 34,204,000Source | -6,427,000Source | -102,539,000Source | -9,939,000Source | -6,206,000Source | -123,955,000Source | 141,703,000Source | -27,298,000Source | -165,268,000Source |
| Operating ExpensesUSD | — | — | — | 159,416,000Source | — | — | — | — | — | — | 1,020,516,000Source | 1,230,449,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,748,000Source | 48,636,000Source | 1,797,000Source | -35,515,000Source | -1,709,000Source | 4,852,000Source | -29,875,000Source | 206,903,000Source | -16,994,000Source | -155,842,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | 8,000,000Source | — | 0Source | 5,000,000Source | 0Source |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 151,669,000Source | 173,632,000Source | 163,580,000Source | 156,807,000Source | 124,196,000Source | 149,952,000Source | 606,879,000Source | 713,142,000Source | 863,495,000Source | 1,004,196,000Source |
| Cost of RevenueUSD | — | — | 101,776,000Source | 133,503,000Source | 83,563,000Source | 107,405,000Source | 78,441,000Source | 107,332,000Source | 400,939,000Source | 494,632,000Source | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 53,804,000Source | 98,203,000Source | 52,924,000Source | 59,597,000Source | 48,607,000Source | 59,086,000Source | 223,002,000Source | 304,220,000Source | 300,559,000Source | 372,672,000Source |
| Operating Income (Loss)USD | — | — | 48,056,000Source | 14,216,000Source | -6,972,000Source | -59,981,000Source | -51,017,000Source | -67,168,000Source | -117,409,000Source | -152,065,000Source | -157,021,000Source | -226,253,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,748,000Source | 48,636,000Source | 1,797,000Source | -35,515,000Source | -1,709,000Source | 4,852,000Source | -29,875,000Source | 206,903,000Source | -16,994,000Source | -155,842,000Source |
| Income Tax Expense (Benefit)USD | — | — | 19,797,000Source | 23,527,000Source | -4,983,000Source | -14,079,000Source | -6,110,000Source | -5,770,000Source | -15,713,000Source | 42,844,000Source | 4,437,000Source | -63,499,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 21,631,000Source | 24,890,000Source | -8,416,000Source | -148,441,000Source | -54,848,000Source | -67,613,000Source | -225,680,000Source | -53,224,000Source | -188,863,000Source | -328,405,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.03Source | 0.04Source | -0.01Source | -0.19Source | -0.07Source | -0.1Source | -0.3Source | -0.08Source | -0.25Source | -0.46Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.03Source | 0.03Source | -0.01Source | -0.19Source | -0.07Source | -0.1Source | -0.3Source | — | — | -0.46Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 777,154,808Source | 694,622,466Source | 755,267,276Source | 788,006,992Source | 758,876,415Source | 671,577,429Source | 751,132,891Source | 694,019,535Source | 751,765,915Source | 719,060,942Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 779,919,259Source | 998,363,636Source | 755,267,276Source | 788,006,992Source | 758,876,415Source | 671,577,429Source | 751,132,891Source | — | — | 719,060,942Source |
| Interest Expense (non-operating)USD | — | — | 11,358,000Source | 17,359,000Source | 11,380,000Source | 70,327,000Source | 10,939,000Source | 15,466,000Source | 108,462,000Source | 47,465,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 19,531,000Source | 20,433,000Source | 18,969,000Source | 19,444,000Source | 18,966,000Source | 19,861,000Source | 77,890,000Source | 82,634,000Source | 86,032,000Source | 87,784,000Source |
| Costs and ExpensesUSD | — | — | 103,613,000Source | 159,416,000Source | 170,552,000Source | 216,788,000Source | 175,213,000Source | 217,120,000Source | 724,288,000Source | 865,207,000Source | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -714,000Source | 28,100,000Source | 4,291,000Source | 10,906,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | -3,938,000Source | -4,324,000Source | -54,026,000Source | 0Source | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 1,100,000Source | 4,100,000Source | 100,000Source | 2,600,000Source | 1,500,000Source | 100,000Source | -2,000,000Source | -3,800,000Source | 1,200,000Source | -1,800,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | -38,000Source | -1,000Source | -65,000Source | 16,000Source | -298,000Source | -273,000Source | -429,000Source | -26,161,000Source | -781,000Source | 649,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | -3,000Source | — | — | — | — | — | — | -107,000Source | -383,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Gross ProfitUSD | — | — | 49,894,000Source | 40,129,000Source | 80,017,000Source | 49,402,000Source | 45,755,000Source | 42,620,000Source | 205,940,000Source | 218,511,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -188,516,000,000Source | 45,796,000Source | -198,394,000Source | -389,439,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -3,000Source | -3,000Source | 0Source | 0Source | -2,000Source | -9,000Source | -29,000Source | -18,000Source | -107,000Source | -383,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | 0Source | — | 13,506,000Source | — |
| Investment Income, InterestUSD | — | — | 3,023,000Source | 2,928,000Source | 3,221,000Source | 3,287,000Source | 3,007,000Source | 4,681,000Source | 14,811,000Source | 8,426,000Source | 3,983,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -6,625,000Source | 34,204,000Source | -6,427,000Source | -102,539,000Source | -9,939,000Source | -6,206,000Source | -123,955,000Source | 141,703,000Source | -27,298,000Source | -165,268,000Source |
| Operating ExpensesUSD | — | — | — | 159,416,000Source | — | — | — | — | — | — | 1,020,516,000Source | 1,230,449,000Source |
| Research and Development ExpenseUSD | — | — | 30,078,000Source | 28,770,000Source | 33,166,000Source | 30,342,000Source | 29,199,000Source | 30,841,000Source | 124,033,000Source | 105,214,000Source | 89,593,000Source | 73,887,000Source |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
Filing attachments
opk-ex99_1.htm · 8-K · 2026-07-27
EX-99.1 2 opk-ex99_1.htm EX-99.1 EX-99.1 OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results Conference Call to Begin Today at 4:30 p.m. ET MIAMI, July 27, 2026 - OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today reports business highlights and financial results for the second quarter ended June 30, 2026. Highlights from t…
Read attachment ↗opk-ex99_1.htm · 8-K · 2026-04-28
EX-99.1 2 opk-ex99_1.htm EX-99.1 EX-99.1 OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, April 28, 2026 - OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026 and recent weeks included the following: • Initiated and completed first dose cohort of MDX2301 Phase 1 clinical tri…
Read attachment ↗opk-ex4_2.htm · 10-K · 2026-02-26
Exhibit 4.4 DESCRIPTION OF COMMON STOCK As of the end of the period covered by the most recent Annual Report on Form 10-K of OPKO Health, Inc.(the “registrant”), the common stock, par value $0.01 per share, of the registrant (the “common stock”) was registered under Section 12 of the Securities Exchange Act of 1934, as amended. Unless the context otherwise requires, all references herein to “we”, “our”, “ours”, and “us” refer to OPKO Health, Inc. The following description of the common stock …
Read attachment ↗opk-ex99_1.htm · 8-K · 2026-02-26
EX-99.1 2 opk-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, February 26, 2026 - OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent w…
Read attachment ↗opk-ex99_1.htm · 8-K · 2025-10-29
EX-99.1 2 opk-ex99_1.htm EX-99.1 EX-99.1 OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, October 29, 2025 - OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: • Entered into a research collaboration with Regeneron Pharma…
Read attachment ↗opk-ex99_1.htm · 8-K · 2025-09-15
EX-99.1 2 opk-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses BURLINGTON, N.C. and MIAMI, September 15, 2025 - Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's acquisition of selec…
Read attachment ↗